The efficacy of neoadjuvant chemotherapy is different for type 4 and large type 3 gastric cancer

In the JCOG0501 study, neoadjuvant chemotherapy (NAC) failed to demonstrate survival benefits for type 4 and large type 3 gastric cancer (GC). The prognosis of these patients is still poor. We conducted this study to explore the value of NAC with non-SP regimens for type 4 and large type 3  GC in the Chinese population.

Source: American Journal of Surgery - October 24, 2023 Category: Surgery Authors: Wei Xu, Lingquan Wang, Wentao Liu, Chen Li, Xuexin Yao, Mingmin Chen, Min Yan, Zhenggang Zhu, Chao Yan Tags: Original Research Article Source Type: research